4 assets in Endocervical Carcinoma

Therapeutic assets addressing Endocervical Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pembrolizumab Endocervical Carcinoma	NGM Biopharmaceuticals, Inc	P1/2	CCC (54)
ngm707 Endocervical Carcinoma	NGM Biopharmaceuticals, Inc	P1/2	CCC (48)
ngm438 Endocervical Carcinoma	NGM Biopharmaceuticals, Inc	P1	CC (43)
ngm831 Endocervical Carcinoma	NGM Biopharmaceuticals, Inc	P1	CC (43)